Mesenchymal stromal cells
Phase 3Biologic
Mario Negri Institute for Pharmacological ResearchMesenchymal stromal cells is one of 162 biologic programs targeting Brain Injury. It is currently in Phase 3.
5
Indications
26
Total Trials
6
Active Trials
161
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Mesenchymal stromal cells
Mario Negri Institute for Pharmacological ResearchPhase 3
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Glucocorticoid
AbbViePreclinical
Statins
SanofiPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-194 trials
Kidney Transplant2 trials
Acute Respiratory Distress Syndrome2 trials
Chronic Graft Versus Host Disease2 trials
Brain Injury1 trial
15 more indications
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Acute Graft Versus Host Disease1 trial
Complication1 trial
Recessive Dystrophic Epidermolysis Bullosa1 trial
Acute Respiratory Failure1 trial
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Completed·—·Phase 1/2·NCT04345601·28 enrolled
Systemic Sclerosis1 trial
Osteogenesis Imperfecta1 trial
Conditioning1 trial
Renal Transplant Recipients1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mesenchymal stromal cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details